Pages

▼
Friday, July 11, 2008

Silence Therapeutics Wins PR Prize in RNAi Therapeutics

›
Silence Therapeutics’ press release following the initiation of the Glover patent opposition hearings has to be counted as yet another examp...
22 comments:

It’s Getting Lonely as Silence and Merck Attempt to Climb Alnylam’s Many RNAi Trigger Patent Walls

›
Today, Alnylam announced the completion of initial oral opposition proceedings concerning the Glover patent EP1230375 for the use of double-...
3 comments:
Sunday, July 6, 2008

The Potential for AAV-mediated RNAi Therapeutics

›
There is good reason to believe that synthetic siRNA-mediated RNAi Therapeutics should emerge as the most commonly used form of RNAi Therape...
5 comments:
Friday, July 4, 2008

Metabolic Disease Drug Development Anxieties Highlight Benefit of Diversified RNAi Therapeutics Pipeline

›
Like the commodity bubble, it seems that the regulatory hurdles to drug development are mounting just when we thought we had reached the top...
2 comments:
Sunday, June 29, 2008

Alnylam’s RSV Program Causes Excitement Among Lung Transplant Surgeons- An Example for a Shrewd RNAi Therapeutics Development Strategy?

›
“Yes, it’s interesting how what we think about most often begins to surround us” replied Chris, a friend from down the hall with whom I shar...
4 comments:
Friday, June 27, 2008

Quark Biotech Dazzles RNAi Therapeutics World with Expanding Pipeline, Adds to Evidence that Delivery Walls to Kidney Crumbling

›
Yesterday, the US-Israeli company Quark Biotech announced the filing of their now third RNAi Therapeutics IND. The latest IND candidate, D...
Tuesday, June 24, 2008

Developing Multi-Functional RNAi Therapeutics

›
The great attraction of developing therapeutics based on RNAi is its inherent specificity and applicability to virtually any gene for the ra...
5 comments: